mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at two different ways to diagnose muscle-invasive bladder cancer (MIBC) to see which one is more accurate. The study will compare the results from a special type of imaging called multi-parametric magnetic resonance imaging (mpMRI) with the results from a procedure called transurethral bladder tumor resection (TURBT), where a doctor removes tissue from the bladder to check for cancer. The goal is to see if the mpMRI can provide clear and accurate information about the cancer stage, as well as how these methods affect patients’ quality of life.

To participate in this trial, individuals must be at least 18 years old and have been identified by their doctor as having suspected muscle-invasive bladder cancer based on an initial examination. They should also be able to understand the study and agree to participate by signing a consent form. Participants will undergo both the mpMRI and the TURBT procedure, and the study will monitor their experiences and outcomes. It’s important to note that people who have had certain treatments or surgeries recently, or those who cannot undergo the imaging or surgery for medical reasons, may not be eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years old or greater at the time of consent.
• • Suspected muscle-invasive bladder cancer by tumor appearance on initial routine cystoscopy as determined by the UCI-affiliated urologist performing this procedure.
• • ECOG Performance Status of 0-3.
• • Patients must have the ability to understand and the willingness to sign a written informed consent document (prior to the initiation of the study and any study procedures).
• • Patients must be willing and able to comply with the scheduled visits, imaging plan, follow up plan, and other specified study procedures in the opinion of the Investigator.
• Exclusion Criteria:
• • Prior TURBT within 120 days of study entry.
• • Prior therapy for bladder cancer within 120 days of study entry.
• • Inability to tolerate mpMRI or associated contrast.
• • Inability to tolerate TURBT or associated anesthesia.
• • ECOG Performance Status of 4.
• • Female patient who is known to be pregnant or breastfeeding.